



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
12961/46102

Application Number 10/766,623	Filing Date January 27, 2004	Examiner Z. C. TUCKER	Art Unit 1624
Invention Title NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES		Inventor Claus MEESE et al.	


Address to:

U.S. Patent and Trademark Office
Customer Window, Mail Stop 313(c)
Randolph Building
Alexandria, VA 22314


SIR:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the enclosed PTO 1449 shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO 1449 (except U.S. patents) is enclosed, unless otherwise noted.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate of this communication is enclosed for charging purposes.

Dated: August 22, 2005


By: Joseph A. Coppola (Reg. No. 38,413)
KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT		Docket Number: 12961/46102	
Application Number 10/766,623	Filing Date January 27, 2004	Examiner Z. C. TUCKER	Art Unit 1624
Invention Title NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES		Inventor Claus MEESE et al.	


Address to:

U.S. Patent and Trademark Office
Customer Window, Mail Stop 313(c)
Randolph Building
Alexandria, VA 22314

SIR:


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the following references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the enclosed PTO 1449 shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO 1449 (except U.S. patents) is enclosed, unless otherwise noted.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate of this communication is enclosed for charging purposes.

Dated: August 22, 2005


By: Joseph A. Coppola (Reg. No. 38,413)
KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449	ATTY. DOCKET NO. 12961/46102	APPLICATION NO. 10/766,263
	APPLICANT Claus MEESE et al.	
	FILING DATE January 27, 2004	GROUP 1624



U. S. PATENT DOCUMENTS*

EXAMINER INITIAL	PATENT/PUBLICATION NUMBER	PATENT/PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	2,556,636	June 12, 1951	Nathan Sperber et al.			
	2,567,245	September 11, 1951	Nathan Sperber et al.			
	2,676,964	April 27, 1954	Nathan Sperber et al.			
	3,261,841	July 19, 1966	Bernard L. Zenitz			

*- copies of U.S. references are not enclosed

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	830,193	February 04, 1952	DE			X	
	685 696	January 07, 1953	GB				
	689 835	April 08, 1953	GB				
	690 274	April 15, 1953	GB				
	692 931	June 17, 1953	GB				
	1 169 944	November 05, 1969	GB				
	1 169 945	November 05, 1969	GB				
	WO 03/021271	March 13, 2003	PCT				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Abstracts from the 26 th Annual Meeting of the International Incontinence Society, August 27-30, 1996, Gillberg et al., abstract 33, Neurology and Urodynamics 15:308-309
	Andersson & Hedlund, "Pharmacological perspective on the physiology of the lower urinary tract," 2002, Urology 60(Suppl. 5A):13-20
	Committee for Proprietary Medicinal Products, "The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products," CPMP/986/96, December 17, 1997
	Gardner & Altman, "Confidence intervals rather than P values: estimation rather than hypothesis testing," 1986, Br. Med. J. 292:746-750
	Kang et al., "Cardiac ion channel effects of Tolterodine," 2004, J. Pharmacol. Exper. Thera. 308:935-940
	Klosa, "Eine Neue Synthesemethode der Darstellung von Diarylalkylaminen," 1966, Journal für Praktische Chemie 4:312-334 (in German) with English translation

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Lipinsky et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings," 1997, Adv. Drug Deliv. Rev. 23:3-25
		Netzer et al., "Screening lead compounds for QT interval prolongation," 2001, Drug Discovery Today 6:78-84
		Nilvebrant et al., "Differences between binding affinities of some antimuscarinic drugs in the parotid gland an those in the urinary bladder and ileum," 1983, Acta Pharmacol. et Toxicol. 53 :304-313
		Pharmacology/Toxicology Review from Application Number 21-518, Center for Drug Evaluation and Research, pages 1-3
		Roy et al., "HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine," 1996, 94:817-823

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	